Tellgen Corporation

Equities

300642

CNE100002P42

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-07-07 pm EDT			5-day change	1st Jan Change
11.2 ^CNY	-3.70%		-3.78%	-36.54%

Jun. 07	Shanghai Maishi Biotechnology Co., Ltd. announced that it has received CNY 20 million in funding from Shanghai Zhangke Lingyi Qifan Venture Capital Center (Limited Partnership), Tellgen Corporation	CI
May. 15	Tellgen Corporation Approves Cash Dividend for 2023	CI

Shanghai Maishi Biotechnology Co., Ltd. announced that it has received CNY 20 million in funding from Shanghai Zhangke Lingyi Qifan Venture Capital Center (Limited Partnership), Tellgen Corporation

June 06, 2024

On June 7, 2024, Shanghai Maishi Biotechnology Co., Ltd. closed the transaction. The transaction was led by new investor, Shanghai Zhangke Lingyi Qifan Venture Capital Center (Limited Partnership) and included participation from returning investor, Tellgen Corporation.

Latest news about Tellgen Corporation

Shanghai Maishi Biotechnology Co., Ltd. announced that it has received CNY 20 million in funding from Shanghai Zhangke Lingyi Qifan Venture Capital Center (Limited Partnership), Tellgen Corporation	Jun. 06	CI
Tellgen Corporation Approves Cash Dividend for 2023	May. 15	CI
Shanghai Maishi Biotechnology Co., Ltd. announced that it expects to receive CNY 20 million in funding from Shanghai Zhangke Lingyi Qifan Venture Capital Center (Limited Partnership), Tellgen Corporation	May. 13	CI
Tranche Update on Tellgen Corporation's Equity Buyback Plan announced on February 6, 2024.	May. 06	CI
Tellgen Corporation's Equity Buyback announced on February 6, 2024, has closed with 1,946,150 shares, representing 1.2% for CNY 25.98 million.	May. 04	CI
Tellgen Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 22	CI
Tranche Update on Tellgen Corporation's Equity Buyback Plan announced on February 6, 2024.	Apr. 01	CI
Tellgen Corporation announces an Equity Buyback for CNY 50 million worth of its shares.	Feb. 06	CI
Tellgen Corporation authorizes a Buyback Plan.	Feb. 05	CI
Tellgen Corporation Announces Board Appointments	Dec. 26	CI
Tellgen Corporation Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-24	CI
Tellgen Corporation, Shanghai Tellgen Diagnostic Technology Co., Ltd., Shanghai Maishi Jingwu Enterprise Management Partnership Enterprise (Limited Partnership), Yao Beier, Niu Zhengxiang and Zhan Hong agreed to acquire additional 5.71% stake in Shanghai Maishi Biotechnology Co., Ltd. from Wu Liang for CNY 1.4 million.	23-09-27	CI
Tellgen Corporation Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-18	CI
Tellgen Corporation Approves Cash Dividend for 2022, Payable on 23 May 2023	23-05-15	CI
Tellgen Corporation Proposes Final Cash Dividend for 2022	23-04-24	CI
Tellgen Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-21	CI
Tellgen Corporation Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Tranche Update on Tellgen Corporation's Equity Buyback Plan announced on October 27, 2021.	22-10-26	CI
Tellgen Corporation's Equity Buyback announced on October 27, 2021, has expired with 1,062,840 shares, representing 0.65% for CNY 25.43 million.	22-10-24	CI
Tranche Update on Tellgen Corporation's Equity Buyback Plan announced on October 27, 2021.	22-10-10	CI
Tellgen Corporation Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-19	CI
Tranche Update on Tellgen Corporation's Equity Buyback Plan announced on October 27, 2021.	22-07-03	CI
Tellgen Corporation Announces Final Distribution on A Shares for the Year 2021, Payable on 24 May 2022	22-05-17	CI
Tellgen Corporation Approves Cash Dividend for the Year 2021	22-05-16	CI
Tellgen Corporation Announces Profit Distribution Proposal for 2021	22-04-25	CI

Chart Tellgen Corporation

Duration

Period

More charts

Company Profile

Tellgen Corp is a company engaged in research, development, production and sales of in vitro diagnostic reagents and instruments. The Company's products are comprised of immunodiagnostic products, molecular diagnostic products and biochemical diagnostic products, including tumor marker detection products, human papillomavirus (HPV) nucleic acid testing products, autoimmune disease detection products and lung cancer methylation mutation detection products.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-26 - Q2 2024 Earnings Release

More about the company

	1st Jan change	Capi.
TELLGEN CORPORATION	-36.54%	259M
BIOMÉRIEUX	-8.55%	12.02B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-22.07%	6.81B
LANTHEUS HOLDINGS, INC.	+27.98%	5.47B
AUTOBIO DIAGNOSTICS CO., LTD.	-24.14%	3.59B
ANDON HEALTH CO., LTD.	+4.11%	2.56B
MYRIAD GENETICS, INC.	+31.82%	2.25B
10X GENOMICS, INC.	-67.01%	2.24B
VITROLIFE AB	-12.07%	2.21B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-17.96%	1.52B

Diagnostic & Testing Substances

Tellgen Corporation

Equities

300642

CNE100002P42

Medical Equipment, Supplies & Distribution

Shanghai Maishi Biotechnology Co., Ltd. announced that it has received CNY 20 million in funding from Shanghai Zhangke Lingyi Qifan Venture Capital Center (Limited Partnership), Tellgen Corporation

Latest news about Tellgen Corporation

Chart Tellgen Corporation

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Diagnostic & Testing Substances